Suppr超能文献

使用活的克隆单菌疫苗对火鸡进行长期保护。

Long-term protection of turkeys with a live clonal monoxenic vaccine.

作者信息

Hatfaludi Tamas, Rezaee Mozhgan Sharokhyan, Vlerick Lise, Sulejmanovic Tarik, De Gussem Maarten, Vereecken Monita, De Gussem Koen, Liebhart Dieter, Hess Michael

机构信息

Clinic for Poultry and Fish Medicine, University of Veterinary Medicine Vienna, Vienna, Austria.

Poulpharm, Izegem, Belgium.

出版信息

Avian Pathol. 2025 Oct;54(5):633-644. doi: 10.1080/03079457.2025.2497814. Epub 2025 May 23.

Abstract

Histomonosis, caused by the protozoan parasite , is a major concern in turkey production due to the lack of licenced drugs and vaccines. Despite various studies on experimental vaccination, the duration of immunity of such a vaccine remains unclear. This study evaluated the long-term efficacy of an attenuated clonal monoxenic culture in turkeys, focusing on its protective effects. Day-old turkeys were vaccinated orally using a frozen vaccine culture directly, without additional multiplication, and challenged 12 weeks later. The vaccine caused no adverse clinical signs, consistent with prior studies. Instead, vaccinated birds had an improved weight gain and higher body-weight at 42 days. Vaccine uptake was confirmed by the detection of histomonad DNA in faeces starting 14 days post-vaccination, coinciding with the first sampling time point, with 60-70% of birds testing positive by 49 days. Considering all sampling time-points before the challenge, every sampled vaccinated turkey secreted histomonads at least once. Following the challenge, analysed clinical scores showed a more than 20-fold reduction in disease severity in vaccinated birds compared to controls, and survival rates were remarkably higher in the vaccinated group (90%) than in non-vaccinated controls (16%). Overall, this study supports the long-term efficacy of the attenuated vaccine, providing robust protection against histomonosis, reducing severity of clinical signs and a significant reduction of mortality, organ lesions as well as parasite burden. The vaccine's effectiveness, when administered at day-old, highlights its potential to prevent histomonosis, though challenges remain for widespread use in commercial turkey farming.Long-term efficacy of attenuated clonal monoxenic vaccine was evaluated in turkeys.Long-term protection: Vaccine-protected turkeys from histomonosis for up to 84 days.Survival: 90% of vaccinated turkeys survived vs. 16% of non-vaccinated birds.Body-weights: Vaccinated birds weighed more, at 42 and 91-105 days of life.Lesions: Fewer liver/caecal lesions in vaccinated birds.

摘要

组织滴虫病由原生动物寄生虫引起,由于缺乏许可的药物和疫苗,它是火鸡养殖中的一个主要问题。尽管对实验性疫苗接种进行了各种研究,但这种疫苗的免疫持续时间仍不清楚。本研究评估了减毒克隆单菌培养物在火鸡中的长期疗效,重点关注其保护作用。一日龄火鸡直接使用冷冻疫苗培养物口服接种,无需额外增殖,并在12周后进行攻毒。该疫苗未引起不良临床症状,与先前的研究一致。相反,接种疫苗的火鸡在42天时体重增加改善且体重更高。从接种疫苗后14天开始,即与第一个采样时间点一致,通过检测粪便中的组织滴虫DNA确认了疫苗摄取情况,到49天时60 - 70%的鸟类检测呈阳性。考虑到攻毒前的所有采样时间点,每个采样的接种疫苗火鸡至少有一次分泌组织滴虫。攻毒后,分析的临床评分显示,与对照组相比,接种疫苗的鸟类疾病严重程度降低了20多倍,接种组的存活率(90%)显著高于未接种对照组(16%)。总体而言,本研究支持减毒疫苗的长期疗效,为组织滴虫病提供了强有力的保护,降低了临床症状的严重程度,并显著降低了死亡率、器官病变以及寄生虫负担。该疫苗在一日龄时给药的有效性突出了其预防组织滴虫病的潜力,尽管在商业火鸡养殖中广泛使用仍面临挑战。在火鸡中评估了减毒克隆单菌疫苗的长期疗效。长期保护:疫苗保护火鸡免受组织滴虫病侵害长达84天。存活率:90%的接种疫苗火鸡存活,未接种鸟类为16%。体重:接种疫苗的火鸡在42天以及91 - 105日龄时体重更重。病变:接种疫苗的鸟类肝脏/盲肠病变较少。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验